NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
Open Access
- 22 April 2008
- journal article
- Published by Springer Nature in Breast Cancer Research
- Vol. 10 (2) , R33
- https://doi.org/10.1186/bcr1996
Abstract
Introduction: Heat shock protein 90 (HSP90) is a key component of a multichaperone complex involved in the post-translational folding of a large number of client proteins, many of which play essential roles in tumorigenesis. HSP90 has emerged in recent years as a promising new target for anticancer therapies. Methods: The concentrations of the HSP90 inhibitor NVP-AUY922 required to reduce cell numbers by 50% (GI50 values) were established in a panel of breast cancer cell lines and patient-derived human breast tumors. To investigate the properties of the compound in vivo, the pharmacokinetic profile, antitumor effect, and dose regimen were established in a BT-474 breast cancer xenograft model. The effect on HSP90-p23 complexes, client protein degradation, and heat shock response was investigated in cell culture and breast cancer xenografts by immunohistochemistry, Western blot analysis, and immunoprecipitation. Results: We show that the novel small molecule HSP90 inhibitor NVP-AUY922 potently inhibits the proliferation of human breast cancer cell lines with GI50 values in the range of 3 to 126 nM. NVP-AUY922 induced proliferative inhibition concurrent with HSP70 upregulation and client protein depletion – hallmarks of HSP90 inhibition. Intravenous acute administration of NVP-AUY922 to athymic mice (30 mg/kg) bearing subcutaneous BT-474 breast tumors resulted in drug levels in excess of 1,000 times the cellular GI50 value for about 2 days. Significant growth inhibition and good tolerability were observed when the compound was administered once per week. Therapeutic effects were concordant with changes in pharmacodynamic markers, including HSP90-p23 dissociation, decreases in ERBB2 and P-AKT, and increased HSP70 protein levels. Conclusion: NVP-AUY922 is a potent small molecule HSP90 inhibitor showing significant activity against breast cancer cells in cellular and in vivo settings. On the basis of its mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, the compound recently has entered clinical phase I breast cancer trials.Keywords
This publication has 36 references indexed in Scilit:
- Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discoveryEmerging Therapeutic Targets, 2008
- Molecular Imaging of the Efficacy of Heat Shock Protein 90 Inhibitors in Living SubjectsCancer Research, 2008
- Drugging the Cancer Chaperone HSP90Annals of the New York Academy of Sciences, 2007
- A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group StudyClinical Cancer Research, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- Progress and new standards of care in the management of HER-2 positive breast cancerEuropean Journal Of Cancer, 2007
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Development and Implementation of a Highly Miniaturized Confocal 2D-FIDA–Based High-Throughput Screening Assay to Search for Active Site Modulators of the Human Heat Shock Protein 90βSLAS Discovery, 2004
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorsNature, 2003
- Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 FunctionJournal of Biological Chemistry, 2002